Table 1.
Patient characteristics
| Characteristic, no. (%) | Discovery cohort (n=40) | Verification cohort (n=127) | ||||
|---|---|---|---|---|---|---|
| IPA 1: Prior acute GVHD− | IPA 2: Prior acute GVHD + | Subsequent chronic GVHD | ||||
| Subsequent chronic GVHD | Subsequent chronic GVHD | |||||
| Yes (n=10) | No (n=10) | Yes (n=10) | No (n=10) | Yes (n=82) | No (n=45) | |
| Prior acute GVHD | 0 (0) | 0 (0) | 10 (100) | 10 (100) | 41 (50) | 24 (53) |
| Median patient age at transplantation (range) | 54 (36–63) | 43 (32–59) | 48 (28–71) | 48 (19–64) | 55 (26–73) | 52 (20–69) |
| Median months from sample collection to chronic GVHD | 2.7 (1.4–5.0) | NA | 5.2 (0.5–16) | NA | 4.9 (0.5–31) | NA |
| Patient gender | ||||||
| Male | 5 (50) | 5 (50) | 5 (50) | 5 (50) | 58 (71) | 25 (56) |
| Female | 5 (50) | 5 (50) | 5 (50) | 5 (50) | 24 (29) | 20 (44) |
| Disease risk at transplantation* | ||||||
| Standard | 5 (50) | 5 (50) | 3 (30) | 5 (50) | 27 (33) | 17 (38) |
| High | 5 (50) | 5 (50) | 7 (70) | 5 (50) | 55 (67) | 28 (62) |
| HLA and donor type | ||||||
| Matched related | 7 (70) | 5 (50) | 6 (60) | 5 (50) | 33 (40) | 19 (42) |
| Matched unrelated | 2 (20) | 3 (30) | 4 (40) | 3 (30) | 36 (44) | 17 (38) |
| HLA mismatched | 1 (10) | 2 (20) | 0 (0) | 2 (20) | 13 (16) | 9 (20) |
| Conditioning regimen | ||||||
| High intensity | 4 (40) | 7 (70) | 5 (50) | 8 (80) | 45 (55) | 21 (47) |
| Reduced intensity | 6 (60) | 3 (30) | 5 (50) | 2 (20) | 37 (45) | 24 (53) |
| Graft source | ||||||
| Bone marrow | 0 (0) | 2 (20) | 0 (0) | 4 (40) | 6 (7) | 11 (24) |
| Mobilized blood cells | 10 (100) | 8 (80) | 10 (100) | 6 (60) | 76 (93) | 32 (71) |
| Umbilical cord blood | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (4) |
| T cell depletion | ||||||
| Antithymocyte globulin | 0 (0) | 1 (10) | 0 (0) | 2 (20) | 1 (1) | 1 (2) |
| Campath | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Immunosuppressive drugs at sample collection | ||||||
| Calcineurin inhibitor | 10 (100) | 10 (100) | 8 (80) | 10 (100) | 80 (98) | 41 (91) |
| Mycophenolate mofetil | 1 (10) | 0 (0) | 2 (20) | 0 (0) | 21 (26) | 12 (27) |
| Sirolimus | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (4) | 1 (2) |
IPA indicates intact protein analysis; GVHD, graft-versus-host disease; and HLA, human leukocyte antigen.
*
The standard-risk category included chronic myeloid leukemia in chronic phase, acute leukemia in first remission, myelodysplastic syndrome without excess blasts, and non-malignant diseases. The high-risk category included all other diseases and stages.